Aligos Therapeutics to Present at Important Conference
Aligos Therapeutics, Inc. (NASDAQ: ALGS), a clinical stage biopharmaceutical company, is dedicated to improving patient outcomes through innovative therapies for liver and viral diseases. Company members will present at the H.C. Wainwright Liver Disease Conference, scheduled for October 21 - 22. This annual conference serves as a significant platform for sharing insights within the liver disease field.
What to Expect from the Presentation
During the conference, Aligos plans to unveil exciting updates on their research and development initiatives aimed at addressing unmet medical needs in chronic liver conditions. The management team will discuss the latest advancements in their therapeutic pipeline, particularly focusing on chronic hepatitis B virus (HBV) infection and metabolic dysfunction-associated steatohepatitis (MASH), both significant issues in today's healthcare landscape.
About Aligos Therapeutics
Aligos Therapeutics has established itself as a pioneer in the biopharmaceutical industry, providing cutting-edge solutions for serious health conditions. Their unique approach combines scientific expertise with innovative technologies to create therapies that meet urgent patient needs.
Pipeline Highlights
The company’s current pipeline includes therapeutics that target chronic hepatitis B, MASH, and developments related to coronaviruses. Aligos' commitment to addressing complex challenges in these areas reflects its mission to deliver best-in-class therapies. By prioritizing research that directly impacts patient well-being, they aim to make a tangible difference in healthcare.
Accessing the Presentation
Investors and interested parties can access a webcast of the presentation directly on the Aligos website in the "Investors" section. This will allow those unable to attend the conference to stay informed about the latest developments and insights shared by the team.
Engaging with Aligos
For ongoing updates and further details about their research projects and corporate strategies, individuals are encouraged to visit Aligos' official website or connect through their LinkedIn and X profiles. Engaging with the company through these platforms provides a more in-depth understanding of their mission and current projects.
Contact Information
For more details or inquiries, individuals can reach out to Jordyn Tarazi, the Vice President of Investor Relations & Corporate Communications, at +1 (650) 910-0427 or via email at jtarazi@aligos.com. Aligos values transparency and encourages communication with its stakeholders.
In addition, media inquiries can be directed to Jake Robison at Inizio Evoke, who serves as Vice President. He can be contacted through email at Jake.Robison@inzioevoke.com.
Frequently Asked Questions
What does Aligos Therapeutics focus on?
Aligos Therapeutics focuses on developing innovative therapies for liver and viral diseases, emphasizing chronic hepatitis B and MASH.
When will Aligos present at the conference?
The presentation will occur during the H.C. Wainwright Liver Disease Conference on October 21 - 22.
How can I access the presentation?
The presentation will be available as a webcast on the Aligos website in the "Investors" section.
What is the company's mission?
Aligos aims to improve patient outcomes by developing best-in-class therapies targeting serious health conditions.
Who can I contact for more information?
For inquiries, you can contact Jordyn Tarazi at +1 (650) 910-0427 or email jtarazi@aligos.com.
